Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised,double-blind,active-controlled,phase 3 trial |
| |
| Affiliation: | 1. Texas Movement Disorder Specialists, Georgetown, TX, USA;2. Selkirk Neurology & Inland Northwest Research, Spokane, WA, USA;3. AbbVie, North Chicago, IL, USA;4. Movement Disorders Unit, Westmead Hospital, Westmead, Australia;5. Sydney Medical School, University of Sydney, Sydney NSW, Australia;6. Royal Adelaide Hospital, Adelaide, SA, Australia;7. Department of Medicine, University of Adelaide, Adelaide, SA, Australia;8. Movement Disorder Clinic of Oklahoma, Tulsa, OK, USA;9. Parkinson and Other Movement Disorders Center, University of California San Diego, La Jolla, CA, USA;10. South Western Sydney Local Health District, Liverpool, NSW, Australia;11. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;12. Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA;13. Steward St Elizabeth''s Medical Center, Brighton, MA, USA;14. University of South Florida Parkinson''s Disease and Movement Disorders Center of Excellence, Tampa, FL, USA |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
